Placental fibroblast growth factor 21 is not altered in late-onset preeclampsia

Reproductive Biology and Endocrinology

Volumn 13, Issue 1, 2015, Pages

  Dekker Nitert, Marloes ^a,b   Scholz Romero, Katherin ^b   Kubala, Marta H ^b   McIntyre, H David ^a,d   Callaway, Leonie K ^a,b,c   Barrett, Helen L ^a,b,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d MATER HOSPITAL   (Australia)

Author keywords

FGF21; GLUT; Placenta; PPAR alpha; PPAR gamma; Preeclampsia

Indexed keywords

FIBROBLAST GROWTH FACTOR 21; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; GLUCOSE TRANSPORTER 4; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; GLUCOSE TRANSPORTER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORD SERUM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFANT; MATERNAL BLOOD; PREECLAMPSIA; PREGNANCY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UMBILICAL CORD BLOOD; WESTERN BLOTTING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PLACENTA;

ADULT; FEMALE; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; HUMANS; PLACENTA; PPAR ALPHA; PPAR GAMMA; PRE-ECLAMPSIA; PREGNANCY; RECEPTORS, FIBROBLAST GROWTH FACTOR; RNA, MESSENGER;

EID: 84926318597     PISSN: None     EISSN: 14777827     Source Type: Journal    
DOI: 10.1186/s12958-015-0006-3     Document Type: Article

References (36)

1. Eiland E, Nzerue C, Faulkner M. Preeclampsia 2012. J Pregnancy. 2012;2012:586578. doi:10.1155/2012/586578.
2. Bellamy L, Casas J-P, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007;335(7627):974.
3. Nerenberg K, Daskalopoulou SS, Dasgupta K. Gestational diabetes and hypertensive disorders of pregnancy as vascular risk signals: an overview and grading of the evidence. Can J Cardiol. 2014;30(7):765-773.
4. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365(9461):785-799.
5. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115(6):1627-35. doi:10.1172/JCI23606.
6. Wente W, Efanov AM, Brenner M, Kharitonenkov A, Koster A, Sandusky GE, et al. Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes. 2006;55(9):2470-8. doi:10.2337/db05-1435.
7. De Sousa-Coelho AL, Relat J, Hondares E, Perez-Marti A, Ribas F, Villarroya F, et al. FGF21 mediates the lipid metabolism response to amino acid starvation. J Lipid Res. 2013;54(7):1786.
8. Ge X, Chen C, Hui X, Wang Y, Lam KS, Xu A. Fibroblast growth factor 21 induces glucose transporter-1 expression through activation of the serum response factor/Ets-like protein-1 in adipocytes. J Biol Chem. 2011;286(40):34533-34541. doi:10.1074/jbc.M111.248591.
9. Mraz M, Bartlova M, Lacinova Z, Michalsky D, Kasalicky M, Haluzikova D, et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf). 2009;71(3):369-375. doi:10.1111/j.1365-2265.2008.03502.x.
10. Li S-M, Wang W-F, Zhou L-H, Ma L, An Y, Xu W-J et al. Fibroblast growth factor 21 expressions in white blood cells and sera of patients with gestational diabetes mellitus during gestation and postpartum. Endocrine. 2014:1-9. doi:10.1007/s12020-014-0309-8.
11. Ribas F, Villarroya J, Hondares E, Giralt M, Villarroya F. FGF21 expression and release in muscle cells: involvement of MyoD and regulation by mitochondria-driven signalling. Biochem J. 2014;463(2):191-199. doi:10.1042/BJ20140403.
12. Tan BK, Sivakumar K, Bari MF, Vatish M, Randeva HS. Lower cerebrospinal fluid/plasma fibroblast growth factor 21 (FGF21) ratios and placental FGF21 production in gestational diabetes. PLoS One. 2013;8(6):e65254. doi:10.1371/journal.pone.0065254.
13. Stepan H, Kley K, Hindricks J, Kralisch S, Jank A, Schaarschmidt W, et al. Serum levels of the adipokine fibroblast growth factor-21 are increased in preeclampsia. Cytokine+. 2013;62(2):322-6. doi:10.1016/j.cyto.2013.02.019.
14. Dekker Nitert M, Barrett HL, Kubala MH, Scholz Romero K, Denny KJ, Woodruff TM, et al. Increased placental expression of fibroblast growth factor 21 in gestational diabetes mellitus. J Clin Endocrinol Metab. 2014;99(4):E591-8. doi:10.1210/jc.2013-2581.
15. Yang C, Jin C, Li X, Wang F, McKeehan WL, Luo Y. Differential Specificity of Endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in Complex with KLB. PLoS One. 2012;7(3):e33870. doi:10.1371/journal.pone.0033870.
16. Muise ES, Azzolina B, Kuo DW, El-Sherbeini M, Tan Y, Yuan X, et al. Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic states. Mol Pharmacol. 2008;74(2):403-412. doi:10.1124/mol.108.044826.
17. Hondares E, Rosell M, Gonzalez FJ, Giralt M, Iglesias R, Villarroya F. Hepatic FGF21 expression is induced at birth via PPARalpha in response to milk intake and contributes to thermogenic activation of neonatal brown fat. Cell Metab. 2010;11(3):206-212. doi:10.1016/j.cmet.2010.02.001.
18. Lowe SA, Brown MA, Dekker GA, Gatt S, McLintock CK, McMahon LP, et al. SOMANZ Guidelines for the management of hypertensive disorders of pregnancy 2008. 2008. https://www.somanz.org/pdfs/somanz_guidelines_2008.pdf.
19. Desoye G, Gauster M, Wadsack C. Placental transport in pregnancy pathologies. Am J Clin Nutr. 2011. doi:10.3945/ajcn.110.000851.
20. He P, Chen Z, Sun Q, Li Y, Gu H, Ni X. Reduced expression of 11beta-hydroxysteroid dehydrogenase type 2 in preeclamptic placentas is associated with decreased PPARgamma but increased PPARalpha expression. Endocrinology. 2013;155(1):299-309. doi:10.1210/en.2013-1350.
21. Holdsworth-Carson SJ, Lim R, Mitton A, Whitehead C, Rice GE, Permezel M, et al. Peroxisome proliferator-activated receptors are altered in pathologies of the human placenta: gestational diabetes mellitus, intrauterine growth restriction and preeclampsia. Placenta. 2010;31(3):222-9. doi:10.1016/j.placenta.2009.12.009.
22. Rodie VA, Young A, Jordan F, Sattar N, Greer IA, Freeman DJ. Human placental peroxisome proliferator-activated receptor delta and gamma expression in healthy pregnancy and in preeclampsia and intrauterine growth restriction. J Soc Gynecol Investig. 2005;12(5):320-329. doi:10.1016/j.jsgi.2005.03.004.
23. Hay Jr WW. Placental-fetal glucose exchange and fetal glucose metabolism. Trans Am Clin Climatol Assoc. 2006;117:321-39. discussion 39-40.
24. Xing AY, Challier JC, Lepercq J, Caüzac M, Charron MJ, Girard J, et al. Unexpected expression of glucose transporter 4 in villous stromal cells of human placenta. J Clin Endocrinol Metab. 1998;83(11):4097-4101.
25. Hauguel-de Mouzon S, Challier JC, Kacemi A, Cauzac M, Malek A, Girard J. The GLUT3 glucose transporter isoform is differentially expressed within human placental cell types. J Clin Endocrinol Metab. 1997;82(8):2689-2694. doi:10.1210/jcem.82.8.4147.
26. Janzen C, Lei MYY, Cho J, Sullivan P, Shin BC, Devaskar SU. Placental glucose transporter 3 (GLUT3) is up-regulated in human pregnancies complicated by late-onset intrauterine growth restriction. Placenta. 2013;34(11):1072-1078. doi:10.1016/j.placenta.2013.08.010.
27. Li K, Li L, Yang M, Liu H, Boden G, Yang G. The effects of fibroblast growth factor-21 knockdown and over-expression on its signaling pathway and glucose-lipid metabolism in vitro. Mol Cell Endocrinol. 2012;348(1):21-26. doi:10.1016/j.mce.2011.07.026.
28. Rajakumar A, Brandon HM, Daftary A, Ness R, Conrad KP. Evidence for the functional activity of hypoxia-inducible transcription factors overexpressed in preeclamptic placentae. Placenta. 2004;25(10):763-769. doi:10.1016/j.placenta.2004.02.011.
29. Semba RD, Crasto C, Strait J, Sun K, Schaumberg DA, Ferrucci L. Elevated serum fibroblast growth factor 21 is associated with hypertension in community-dwelling adults. J Hum Hypertens. 2013;27(6):397-399. doi:10.1038/jhh.2012.52.
30. Yang SJ, Hong HC, Choi HY, Yoo HJ, Cho GJ, Hwang TG, et al. Effects of a three-month combined exercise programme on fibroblast growth factor 21 and fetuin-A levels and arterial stiffness in obese women. Clin Endocrinol (Oxf). 2011;75(4):464-9. doi:10.1111/j.1365-2265.2011.04078.x.
31. Gallego-Escuredo JM, Gomez-Ambrosi J, Catalan V, Domingo P, Giralt M, Fruhbeck G, et al. Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients. Int J Obes. 2015;39(1):121-9. doi:10.1038/ijo.2014.76.
32. Stein S, Stepan H, Kratzsch J, Verlohren M, Verlohren H-J, Drynda K, et al. Serum fibroblast growth factor 21 levels in gestational diabetes mellitus in relation to insulin resistance and dyslipidemia. Metabolism. 2010;59(1):33-37. doi:10.1016/j.metabol.2009.07.003.
33. Scioscia M, Gumaa K, Rademacher TW. The link between insulin resistance and preeclampsia: new perspectives. J Reprod Immunol. 2009;82(2):100-105. doi:10.1016/j.jri.2009.04.009.
34. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes. 2008;57(5):1246-1253. doi:10.2337/db07-1476.
35. Han SH, Choi SH, Cho BJ, Lee Y, Lim S, Park YJ, et al. Serum fibroblast growth factor-21 concentration is associated with residual renal function and insulin resistance in end-stage renal disease patients receiving long-term peritoneal dialysis. Metabolism. 2010;59(11):1656-1662. doi:10.1016/j.metabol.2010.03.018.
36. Mericq V, De Luca F, Hernandez MI, Peña V, Rossel K, Garcia M, et al. Serum fibroblast growth factor 21 levels are inversely associated with growth rates in infancy. Horm Res Paediatr. 2014;82(5):324-331.